AR125330A1 - Combinación que comprende everolimus y amcenestrant - Google Patents
Combinación que comprende everolimus y amcenestrantInfo
- Publication number
- AR125330A1 AR125330A1 ARP220100914A ARP220100914A AR125330A1 AR 125330 A1 AR125330 A1 AR 125330A1 AR P220100914 A ARP220100914 A AR P220100914A AR P220100914 A ARP220100914 A AR P220100914A AR 125330 A1 AR125330 A1 AR 125330A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- amcenestrant
- everolimus
- pharmaceutical composition
- combination
- Prior art date
Links
- KISZAGQTIXIVAR-VWLOTQADSA-N 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid Chemical compound ClC1=C(C=CC(=C1)Cl)C1=C(C2=C(CCC1)C=C(C=C2)C(=O)O)C1=CC=C(C=C1)O[C@@H]1CN(CC1)CCCF KISZAGQTIXIVAR-VWLOTQADSA-N 0.000 title abstract 5
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 title abstract 5
- 229940070192 amcenestrant Drugs 0.000 title abstract 5
- 229960005167 everolimus Drugs 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 3
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En el presente documento se proporciona una combinación de everolimus y de amcenestrant o una sal farmacéuticamente aceptable de los mismos, una composición farmacéutica que contiene tal combinación, y los usos terapéuticos de los mismos, en particular para el tratamiento del cáncer, incluido el cáncer de mama. Reivindicación 1: Una combinación que comprende amcenestrant, o una sal farmacéuticamente aceptable del mismo, y everolimus. Reivindicación 6: Una composición farmacéutica que comprende amcenestrant, o una sal farmacéuticamente aceptable del mismo y everolimus y al menos un excipiente farmacéuticamente aceptable. Reivindicación 13: Un kit farmacéutico que comprende: (i) una primera composición farmacéutica que comprende amcenestrant o una sal farmacéuticamente aceptable del mismo, y al menos un excipiente farmacéuticamente aceptable; (ii) una segunda composición farmacéutica que comprende everolimus y al menos un excipiente farmacéuticamente aceptable; en donde la primera composición farmacéutica y la segunda composición farmacéutica se encuentran en compartimentos separados y están destinadas a administrarse de forma independiente, siendo cada administración con respecto a la otra simultánea o espaciada en el tiempo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21315063 | 2021-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125330A1 true AR125330A1 (es) | 2023-07-05 |
Family
ID=75825773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100914A AR125330A1 (es) | 2021-04-12 | 2022-04-11 | Combinación que comprende everolimus y amcenestrant |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240197692A1 (es) |
| EP (1) | EP4322942A1 (es) |
| JP (1) | JP2024516795A (es) |
| CN (1) | CN117177743A (es) |
| AR (1) | AR125330A1 (es) |
| TW (1) | TW202304424A (es) |
| WO (1) | WO2022218958A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015022609A1 (en) * | 2013-08-14 | 2015-02-19 | Novartis Ag | Combination therapy for the treatment of cancer |
| CN108884079B (zh) | 2016-02-15 | 2021-03-05 | 赛诺菲 | 作为雌激素受体调节剂的6，7-二氢-5h-苯并[7]轮烯衍生物 |
| CA3169679A1 (en) * | 2020-03-06 | 2021-09-10 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
-
2022
- 2022-04-08 TW TW111113410A patent/TW202304424A/zh unknown
- 2022-04-11 AR ARP220100914A patent/AR125330A1/es unknown
- 2022-04-12 US US18/286,496 patent/US20240197692A1/en active Pending
- 2022-04-12 WO PCT/EP2022/059704 patent/WO2022218958A1/en active Application Filing
- 2022-04-12 CN CN202280027705.5A patent/CN117177743A/zh active Pending
- 2022-04-12 JP JP2023562510A patent/JP2024516795A/ja active Pending
- 2022-04-12 EP EP22722256.9A patent/EP4322942A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022218958A1 (en) | 2022-10-20 |
| TW202304424A (zh) | 2023-02-01 |
| EP4322942A1 (en) | 2024-02-21 |
| CN117177743A (zh) | 2023-12-05 |
| US20240197692A1 (en) | 2024-06-20 |
| JP2024516795A (ja) | 2024-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078588A1 (es) | Combinaciones de un inhibidor de pi3k y un inhibidor de mek | |
| AR078224A1 (es) | Composicon para el tratamiento del cancer de prostata | |
| JP2012503666A5 (es) | ||
| Gu et al. | Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia | |
| AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
| JP2012180381A5 (es) | ||
| AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
| ECSP10010011A (es) | Composición farmacéutica que comprende la combinación de diversos agentes venotónicos vasoprotectores para el tratamiento de la insuficiencia venosa crónica | |
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| de la Rubia et al. | FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies | |
| ES2395401T3 (es) | kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer | |
| CO2022008437A2 (es) | Métodos de tratamiento del cáncer de pulmón de cé-lulas pequeñas con formulaciones de lurbinectedina | |
| CO2022015891A2 (es) | Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres | |
| CL2021003034A1 (es) | Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| ES2656913T3 (es) | Endrogenina A y agentes antineoplásicos para el tratamiento de tumores quimiosensibles o quimiorresistentes | |
| JP2019526559A5 (es) | ||
| AR125330A1 (es) | Combinación que comprende everolimus y amcenestrant | |
| AR123227A1 (es) | Terapias combinadas para su uso en el tratamiento del cáncer | |
| AR041947A1 (es) | Uso de acetil-l-carnitina o de una sal farmaceuticamente aceptable de la misma para la preparacion de un medicamento para prevenir y/o tratar las neuropatias perifericas inducidas por la administracion de un agente anticancer que induce neuropatias perifericas | |
| DOP2010000265A (es) | Formulacion galenica oral que comprende ketorolaco y vitaminas del complejo b, en la que la vitamina b6 se encuentra em una capa externa separada del resto de principios activos | |
| CO6331430A2 (es) | Composicion farmaceutica que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b para el tratamiento de la neuralgia | |
| Hayashi et al. | Voriconazole vs. itraconazole for antifungal prophylaxis in patients with GVHD: a randomized trial | |
| EL-Hak et al. | Influence of injection mode and antioxidant dietary on the toxicity of Doxorubicin as a chemotherapy drug | |
| AR125331A1 (es) | Combinación que comprende ribociclib y amcenestrant |